Core Insights - PetVivo Holdings, Inc. will exhibit at the Veterinary Meeting & Expo Conference from January 25th to January 29th, 2025, in Orlando, Florida [1] - The company will showcase its lead product, Spryng with OsteoCushion Technology, which is designed to manage joint pain in animals [2][7] - The VMX Conference is the largest veterinary conference in the U.S., attracting top industry professionals [3] Product Information - Spryng is an intra-articular injectable veterinary medical device made of sterilized, extra-cellular matrix microparticles that integrate with the animal's subsynovial tissue [2] - The product aims to restore proper joint mechanics and manage noninfectious joint pain sources, including joint instability, degenerative joint disease, and osteoarthritis [2][7] Company Overview - PetVivo Holdings focuses on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals [6] - The company has developed a robust pipeline of products and holds a portfolio of 21 patents protecting its biomaterials and methods of use [7] - PetVivo's strategy includes developing human therapies for companion animals in a capital and time-efficient manner, allowing for quicker market entry compared to human pharmaceuticals [6]

MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) ("PetVivo"), a pioneering biomedical technology company focused on adapting human biotech, medical device and other therapeutic technologies into osteoarthritis and lameness products for commercial sale in the US companion animal and equine markets, announces new distribution partnerships with Vedco Inc. (“Vedco”), and Clipper Distributing, LLC (“Clipper”), both leaders in logistical solutions and supply of products ...

MINNEAPOLIS, MN, US, Dec. 30, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will host a live webcast Shareholders Update Meeting to provide an overview of the Company’s progress in the 2025 fiscal year and a look into the potential future of the Company. The Shareholders Update Meeting: 2025 Company Overview will be held on Wednesday, January 8, 2025 at 3:30 p.m. ...

MINNEAPOLIS, MN, Nov. 26, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, will exhibit at the American Association of Equine Practitioners (“AAEP”) convention to be held December 8th to December 10th, 2024 at the Orange County Convention Center, Exhibit Halls B, C and D, in Orlando, Florida. PetVivo will exhibit its lead product, Spryng ™ with OsteoCushion™ Technology. Spryng is an intr ...

MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal second quarter ended September 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time November 14, 2024 to discuss the results (see dial-in information below). Fiscal Q2 202 ...

MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. “Cindy’s experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals,” ...

Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Sept. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic devices for equines and companion animals, has appointed board certified veterinary surgeon, Dr. Kirsty Husby, DVM, MS, DACVS (LA), to the position of senior technical services ...

MINNEAPOLIS, MN, US, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Scot Cave has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover the Northwest Region of the United States. "The addition of Scot to our sales and distribu ...

MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Anthony Germinaro has accepted a position with the Company as its new Field Veterinary Business Development Manager for the for the Southwest Region of the United States. "Adding Anthony to our sales and distr ...

Core Viewpoint - PetVivo Holdings, Inc. is experiencing growth in revenue and operational milestones, driven by the adoption of its flagship product, Spryng with OsteoCushion technology, and is reiterating its revenue guidance for fiscal 2025, expecting a growth of 50% to 100% compared to the previous year [1][13]. Financial Highlights - Revenues for fiscal Q1 2025 increased by 6% to $124,000, attributed to the rollout of Spryng [3][14]. - Sales to distributors surged by 102% to $68,000, indicating strong demand and expansion of the distributor network [3]. - Gross profit rose by 6% to $111,000, maintaining a gross margin of 89.5% [3][14]. - The net loss improved to $2.0 million or $(0.11) per share, compared to a net loss of $2.9 million or $(0.25) per share in the same quarter last year, due to cost-reduction strategies [3][16]. Operational Highlights - Spryng is now distributed in over 800 veterinary clinics across all 50 states, with more than 10,000 syringes sold [4]. - Key appointments include April Boyce as VP of Marketing and Bryan Monninger as VP of Sales, both bringing extensive experience from major companies [4][8]. - The company showcased Spryng at significant veterinary conferences, enhancing its visibility among industry experts [4][12]. Strategic Outlook - The company plans to accelerate market adoption of Spryng through additional key hires and strengthening its sales and marketing teams [7][9]. - Ongoing clinical studies, including one at Colorado State University, are expected to bolster the product's credibility and support distribution strategies [10][11]. - PetVivo is positioned to capitalize on the growing $5.7 billion U.S. animal health market, projected to reach $11.3 billion by 2030 [13]. Revenue Guidance - For fiscal 2025, the company anticipates net revenue between $1.5 million and $2.0 million, reflecting a growth of approximately 50% to 100% over the prior year [13].